Abstract:Selenoprotein glutathione peroxidases (GPX), like ubiquitously expressed GPX1 and the ferroptosis modulator GPX4, enact antioxidant activities by reducing hydroperoxides using glutathione. Overexpression of these enzymes is common in cancer and can be associated with the development of resistance to chemotherapy. GPX1 and GPX4 inhibitors have thus shown promise as anti-cancer agents, and targeting other GPX isoforms may prove equally beneficial. Existing inhibitors are often promiscuous, or modulate GPXs only indirectly, so novel direct inhibitors identified through screening against GPX1 and GPX4 could be valuable. Here, we developed optimized glutathione reductase (GR)-coupled GPX assays for the biochemical high-throughput screen (HTS) of almost 12,000 compounds with proposed mechanisms of action. Initial hits were triaged using a GR counter-screen, assessed for isoform specificity against an additional GPX isoform, GPX2, and were assessed for general selenocysteine-targeting activity using a thioredoxin reductase (TXNRD1) assay. Importantly, 70% of the GPX1 inhibitors identified in the primary screen, including several cephalosporin antibiotics, were found to also inhibit TXNRD1, while auranofin, previously known as a TXNRD1 inhibitor, also inhibited GPX1 (but not GPX4). Additionally, every GPX1 inhibitor identified (including omapatrilat, tenatoprazole, cefoxitin and ceftibuten) showed similar inhibitory activity against GPX2. Some compounds inhibiting GPX4 but not GPX1 or GPX2, also inhibited TXNRD1 (26%). Compounds only inhibiting GPX4 included pranlukast sodium hydrate, lusutrombopag, brilanestrant, simeprevir, grazoprevir (MK-5172), paritaprevir, navitoclax, venetoclax and VU0661013. Two compounds (metamizole sodium and isoniazid sodium methanesulfate) inhibited all three GPXs but not TXNRD1, while 2,3-dimercaptopropanesulfonate, PI4KIII beta inhibitor 3, SCE-2174 and cefotetan sodium inhibited all tested selenoproteins (but not GR). The detected overlaps in chemical space suggest that the counter screens introduced here should be imperative for identification of specific GPX inhibitors. With this approach, we could indeed identify novel GPX1/GPX2- or GPX4-specific inhibitors, thus presenting a validated pipeline for future identification of specific selenoprotein-targeting agents. Our study also identified GPX1/GPX2, GPX4 and/or TXNRD1 as targets for several previously developed pharmacologically active compounds.

Small-molecule allosteric inhibitors of GPX4

Discovery of a Potent Chloroacetamide GPX4 Inhibitor with Bioavailability to Enable Target Engagement in Mice, a Potential Tool Compound for Inducing Ferroptosis in Vivo.

Selective covalent targeting of GPX4 using masked nitrile-oxide electrophiles

Novel Allosteric Activators for Ferroptosis Regulator Glutathione Peroxidase 4.

Structure-activity relationship study of RSL3-based GPX4 degraders and its potential noncovalent optimization

Discovery of GPX4 inhibitors through FP-based high-throughput screening

Novel Covalent Probe Selectively Targeting Glutathione Peroxidase 4 In Vivo: Potential Applications in Pancreatic Cancer Therapy

Development of an assay pipeline for the discovery of novel small molecule inhibitors of human glutathione peroxidases GPX1 and GPX4

Research progress on GPX4 targeted compounds

Molecular Mechanism Study of EGFR Allosteric Inhibitors Using Molecular Dynamics Simulations and Free Energy Calculations

GPX4 allosteric activators inhibit ferroptosis and exert myocardial protection in doxorubicin-induced myocardial injury mouse model

Discovery of Novel Glutaminase 1 Allosteric Inhibitor with 4-Piperidinamine Linker and Aromatic Heterocycles.

Design, Synthesis, and Biological Evaluation of Novel Glutaminase 1 Allosteric Inhibitors with an Alkane Chain Tail Group.

Ligandability at the membrane interface of GPx4 revealed through a reverse micelle fragment screening platform

Design and Synthesis of Proteolysis-Targeting Chimeras (protacs) As Degraders of Glutathione Peroxidase 4.

Design, Synthesis, and Biological Evaluation for First GPX4 and CDK Dual Inhibitors

Characterization of a patient-derived variant of GPX4 for precision therapy

Structure-activity relationships of GPX4 inhibitor warheads

Targeting GPX4 in ferroptosis and cancer: chemical strategies and challenges

Enhancing the Affinity of Novel GLS1 Allosteric Inhibitors by Targeting Key Residue Lys320.

Erastin-like anti-Warburg compounds X1 and X4 are GLS2-selective covalent glutaminase inhibitors